Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapyCaitlin D. Lowery(Eli Lilly (United States)), Beverly L. Falcón(University of California, San Francisco)OncotargetSeptember 17, 201910.18632/oncotarget.27148Cited by 18SaveCiteExport RISWatch citationsRelated PapersReduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors|Cancer Research|2011|91